Imagawa A,Hanafusa T,Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies.Osaka IDDM Study Group[J].N Engl J Med,2000,342(5):301-307.
[2]
Imagawa A,Hanafusa T,Uchigata Y,et al.Fulminant type 1 diabetes: a nationwide survey in Japan[J].Diabetes Care,2003,26(8):2345-2352.
[3]
Kim N H, Kim H Y, Seo J A, et al.A pooled analysis of 29 patients with fulminant type 1 diabetes in Korea: a comparison with a nationwide survey in Japan[J].Diabetes Res Clin Pract,2009,86(3):e43-45.
[4]
Cho Y M,Kim J T,Ko K S,et al.Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes[J]. Diabetologia ,2007,50(11):2276-2279.
Chiou C C,Chung W H,Hung S I,et al.Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection[J].J Am Acad Dermatol,2006,54(2):S14-S17.
Hanafusa T,Imagawa A.Fulminant type l diabetes a novel clinical entity requiring special attention by all medical practitioners[J].Nat ClinPractEndocrinolMatab,2007,3(1):36-45.
[13]
Tanaka S, Kobayashi T,Momotsu T. A novel subtype of type 1 diabetes mellitus[J]. N Engl J Med, 2000,342(24):1835-1836.
[14]
Takaike H. Transient elevation of liver transaminase after starting insulin therapy for diabetic ketosis or ketoacidosis in newly diagnosed type 1 diabetes mellitus[J]. Diabetes Res ClinPract,2004,64(5):27-32.
[15]
Bronstein H D,Kantrowitz P A, Schaffner F.Marked Enlargement of the liver and transient ascites associated with the treatment of diabetic acidosis[J].N Engl J Med,1959,261:1314-1318.
[16]
Shimizu I, Makino H, Imagawa A,et al. Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy[J]. The Journal of clinical endocrinology and metabolism,2006,91(2):471-476.
[17]
mutase Y,Imagawa A,hanafusa T,et al.Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy-a nationwide 5-year-study in Japan[J].Diabetologia,2007,50(3):531-537.
[18]
Takaike H,Uchigata Y,Nakagami T,et al.Incidenceand development of diabetic microangiopathy of fulminant type 1 diabetes-comparison with non-fulminant type l diabetes[J].Intern Med,2010,49(12):1079-1083.
[19]
Kim B Y. Jung C H. MokJ O,et al. Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients[J].Actadiabetologica,2012,49(1):9-15.
[20]
Panero F, Novelli G, Zucco C,et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients[J]. Diabetes Care,2009,32(1):301-305.
2017, Vol. 28 
